Dry powder inhaler (DPI) is an attractive dosage form for local and systemic pulmonary drug
delivery. However, designing DPIs with adequate physicochemical properties is …

In vitro dissolution and permeability testing aid the simulation of the in vivo behavior of
inhalation drug products. Although the regulatory bodies have specific guidelines for the …

Dry powder inhalers (DPIs) are regularly used to treat respiratory diseases. Adding extrinsic
fine excipient particles to the blend of active pharmaceutical ingredient (API) and carrier is …

The bioaerogel microparticles have been recently developed for respiratory drug delivery
and attract fast increasing interests. These highly porous microparticles have ultralow …

Almost all current orally inhaled drug products (OIDPs) are for the treatment of respiratory
diseases, and many have been designed using molecular or formulation strategies to retain …

Dry powder inhalers (DPIs) are commonly used devices for delivering inhalable
pharmaceuticals. The overall efficacy of any inhalable pharmaceutical is a function of total …

Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are
versatile means for the highly efficient delivery of budesonide. However, uncontrolled …

This work illustrates the development of a dry inhalation powder of cyclosporine-A for the
prevention of rejection after lung transplantation and for the treatment of COVID-19. The …

The lung is an attractive site for drug delivery for both local and systemic effects due to its
large surface area and rapid drug absorption by lung cells. Drug delivery to the lungs can be …

Pulmonary drug delivery has been used for decades to treat local diseases like asthma.
When using the pulmonary route to deliver drugs, several important lung features are being …